Amer Khiyami

Dr. Amer Khiyami

MetroHealth Medical Center, Cleveland, Georgia, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GGGeorge Boon Bee Goh
George Boon Bee Goh
MPMangesh R. Pagadala
Mangesh R. Pagadala
JDJaividhya Dasarathy
Jaividhya Dasarathy
AUAynur Unalp-Arida
Aynur Unalp-Arida
RPRish K. Pai
Rish K. Pai
AMArthur J. McCullough
Arthur J. McCullough

13 February 2023 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
KEKirsten Eom
Kirsten Eom
KBKristen A. Berg
Kristen A. Berg
NJNatalie E. Joseph
Natalie E. Joseph
KRKristen Runner
Kristen Runner
YTYasir Tarabichi
Yasir Tarabichi
Khalid Sossey-AlaouiKhalid Sossey-Alaoui
Khalid Sossey-Alaoui

25 November 2007 in Journal of Medical Case Reports
Verified
Journal Article
Open access
VSVivek Subbiah
Vivek Subbiah
ULUyen K Ly
Uyen K Ly
AKAmer Khiyami
Amer Khiyami
TOTimothy O'BRien
Timothy O'BRien
Thirty two year old Caucasian female presented 2 months post partum with fevers, cough and shortness of breath. CT scan of the chest to rule out pulmonary embolism revealed mediastinal lymphadenopathy. Biopsy of the nodes revealed classic Hodgkin's lymphoma and she received ABVD chemotherapy. She was in remission as confirmed by a PET/CT scan. Five months later she had another PET/CT scan which showed areas of hypermetabolism indicating a possible relapse. Biopsy revealed sarcoidosis. She received steroids and 18 months later remained in clinical remission. This rare case of sarcoid following classic Hodgkin's lymphoma illustrates that clinical presentation, physical exam, lab investigations and even PET/CT scans may not be able to discriminate between Hodgkin's lymphoma and sarcoidosis. Tissue biopsy and pathological diagnosis remain the gold standard.

12 May 2017 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
SJSarmad H. Jassim
Sarmad H. Jassim
AKAmer Khiyami
Amer Khiyami
JNJane K. Nguyen
Jane K. Nguyen
SGSanthi Ganesan
Santhi Ganesan
JTJoseph Tomashefski
Joseph Tomashefski
JSJoram Sawady
Joram Sawady
Clear cell carcinoma of the bladder is a rare variant of urinary bladder adenocarcinoma. We report a case of a patient with clear cell carcinoma of the bladder and a concordant right upper lobe pulmonary adenocarcinoma with clear cell features, and we address the role of immunohistochemistry and cytogenetic analysis in distinguishing the two primary malignancies. Our patient was a 59-year-old African American woman who presented with hematuria. Her past medical history included invasive mammary carcinoma and end-stage renal disease treated with hemodialysis. A computed tomographic urogram revealed a 3-cm polypoid bladder mass. A follow-up chest computed tomographic scan revealed a 1-cm right upper lobe nodule. The patient underwent transurethral biopsy and subsequent radical cystectomy, as well as a transthoracic core needle biopsy of the lung nodule. Histologically, the bladder tumor consisted of flat, cuboidal to columnar cells with clear or eosinophilic cytoplasm and a hobnail appearance, organized in tubulocystic and papillary patterns. The neoplastic cells were diffusely positive for α-methylacyl-coenzyme A racemase, cancer antigen 125, and cytokeratin 7; focally positive for cytokeratin 20, P53, and carcinoembryonic antigen; and negative for thyroid transcription factor 1. The lung tumor demonstrated a glandular architecture with mucin production (positive for mucin with mucicarmine and periodic acid-Schiff with diastase stain). The neoplastic cells were diffusely positive for cytokeratin 7, napsin A, and thyroid transcription factor 1, and they were negative for cytokeratin 20 and cancer antigen 125. Genetic testing of the pulmonary neoplasm demonstrated ARID2 genomic alterations. The presence of clear cell features in both neoplasms raised the possibility of lung metastasis from the primary bladder tumor. However, the glandular architecture of the lung neoplasm along with its distinctive immunohistochemical and genetic profiles confirmed the presence of two separate primaries.

15 July 2004 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JTJ. E. Trey
J. E. Trey
JSJ. E. Simon
J. E. Simon
AKAmer Khiyami
Amer Khiyami
764 Background: Leptomeningeal carcinomatosis is a rare complication of breast cancer. Standard treatment includes intrathecal methotrexate and radiation. The results of therapy are unsatisfactory and the prognosis is poor. Methods: We report two patients with breast cancer and meningeal involvement who responded to systemic chemotherapy with carboplatinum (AUC6) and docetaxel (75mg/M2. This regimen was chosen because of the preclinical synergy of these agents, proven efficacy in metastatic breast cancer, and the ability of carboplatinum to treat brain tumors. Results: Patient #1 developed isolated leptomeningeal disease 18 months after responding to neoadjuvant therapy with cyclophosphamide and doxorubicin for locally advanced breast cancer. She was originally treated with intrathecal methotrexate without response, followed by craniospinal irradiation with clinical stabilization. Eighteen months after radiation she again developed symptomatic meningeal disease along with early metastases in lung and liver. Treatment with carboplatinum and docetaxel was begun. Clinical response was prompt and MRI demonstrated improvement. Repeat CSF cytology showed only degenerating cells. She remained neurologically stable for more than 12 months. Patient #2 had previously undergone resection and cranial irradiation of cerebellar metastases from breast cancer and subsequent chemotherapy for metastatic disease with paclitaxel and trastuzumab when she developed symptomatic leptomeningeal disease. Based on the response in our previous patient, she was treated with carboplatinum and docetaxel. Trastuzumab was continued as her brain tumor overexpressed HER2/neu. Her symptoms improved, and repeat MRI and CSF exams documented response. She remains stable after 11 months of treatment. Conclusions: Systemic chemotherapy with carboplatinum and docetaxel (+trastuzumab)can be effective in the treatment of meningeal carcinomatosis from breast cancer. This regimen deserves formal study and comparison to standard treatments No significant financial relationships to disclose.